Re: [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.

Adeleke, Sola; Haroon, Athar; Kasivisvanathan, Veeru

Re: [¹⁷⁷Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial.

Adeleke, Sola; Haroon, Athar; Kasivisvanathan, Veeru.

Afiliación

Adeleke S; School of Cancer & Pharmaceutical Sciences, King's College London, London, UK; Department of Oncology, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK. Electronic address: sesola2003@gmail.com.
Haroon A; Department of Nuclear Medicine, Bart's Health NHS Trust, St. Bartholomew's Hospital, London, UK.
Kasivisvanathan V; Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.

Eur Urol ; 80(1): 118-119, 2021 07.

Article en En | MEDLINE | ID: mdl-33875309

Asunto(s)

Neoplasias de la Próstata Resistentes a la Castración; Dipéptidos; Compuestos Heterocíclicos con 1 Anillo; Humanos; Masculino; Antígeno Prostático Específico; Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico; Taxoides

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials Límite: Humans / Male Idioma: En Revista: Eur Urol Año: 2021 Tipo del documento: Article Pais de publicación: CH / SUIZA / SUÍÇA / SWITZERLAND

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google